Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
9.84
-0.65 (-6.20%)
At close: Nov 17, 2026, 4:00 PM EST
10.14
+0.30 (3.09%)
After-hours: Nov 17, 2026, 7:50 PM EST
Generate Biomedicines Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Generate Biomedicines stock has a consensus rating of "Strong Buy" and an average price target of $27. The average 1-year stock price forecast is 174.39% higher than the current stock price, while the lowest is $22 (+123.58%) and the highest is $30 (+204.88%).
Price Target: $27 (+174.39%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Generate Biomedicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 → $30 | Buy | Reiterates | $25 → $30 | +204.88% | Nov 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $26 | Buy | Reiterates | $26 | +164.23% | Oct 14, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $22 | Buy | Reiterates | $22 | +123.58% | Aug 17, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $30 | Buy | Reiterates | $30 | +204.88% | Jun 25, 2026 |
Financial Forecast
Revenue This Year
24.82M
from 31.89M
Decreased by -22.17%
Revenue Next Year
24.00M
from 24.82M
Decreased by -3.31%
EPS This Year
-2.45
EPS Next Year
-2.38
from -2.45
EPS and Forward PE are based on non-GAAP adjusted numbers.